Vnitr Lek 2023, 69(6):387-390 | DOI: 10.36290/vnl.2023.075

Heart failure as the first clinical symptom of amyloidosis

František Novák1, Jan Václavík2
1 Interní oddělení Podhorské Nemocnice Agel, Bruntál
2 Interní a kardiologická klinika Fakultní nemocnice Ostrava a Lékařská fakulta Ostravské univerzity

The term amyloidosis includes a group of disorders in which proteins, both native and mutated, are deposited in the tissues. These proteins form an ordered fibrous, poorly soluble matrix called amyloid. Its deposition impairs the function of the affected organs (1, 2). Diagnosis is difficult and often late (3). Heart involvement is very common and limits the prognosis of the patient (4). We describe the case of a patient in which even the relatively early diagnosis did not prevent her sudden death.

Keywords: cardiac amyloidosis, diagnosis, sudden cardiac death.

Accepted: September 21, 2023; Published: October 10, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novák F, Václavík J. Heart failure as the first clinical symptom of amyloidosis. Vnitr Lek. 2023;69(6):387-390. doi: 10.36290/vnl.2023.075.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dubrey S. Amyloid heart disease. Brit. Jour. Card. 2009;16:36-41.
    2. Adam Z, Sčudla V, Hájek R, et al. Diagnostika a léčba systémové AS amyloidózy. Doporučení CMG a myelomové sekce CHS CLS JEP. Tansf. Hematol. Dnes 2013;19:suppl.
    3. Zahradová L. Systémová amyloidóza. Onkológia. 2016;11(6):361-364.
    4. Hassan W, Al­‑Segrani H, Mourad W et al. Amyloid Heart Disease. Tex. Heart Inst. J. 2005;32:178-184.
    5. Lachmann HJ, Goodman HJB, Gillberton JA, et al. Natural History and Outcome in Systemic AA amyloidosis. N Engl J Med. 2007;356:2361-2371. Go to original source... Go to PubMed...
    6. Wechelekar AD, Gillmore JD, Hawkins PN. Systemic Amyloidosis. Lancet. 2016;387(10038):2641-2654. Go to original source... Go to PubMed...
    7. Ryšavá R. Systémové amyloidózy a jejich léčba. Praha: Maxdorf Jessenius, 2013.
    8. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised Prognostic Paging System forLight Chain Amyloidosis Incorporatin Cardiac Biomarkers and Serum Free Light Chain Measurement. J Clin Oncol. 2012;30:989-995. Go to original source... Go to PubMed...
    9. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic Implantation of Cardioverter­‑defibrillator in Patients with Severe Cardiac Amyloidosis and High Risk for Sudden Cardiac Death, Heart Rhythm. 2008;254-255. Go to original source... Go to PubMed...
    10. Merlini G, Seldin DC, Gertz MA. Amyloidosis; Pathogenesis and New Therapeutic Options. J Clin Oncol. 2011;29:1924-1933. Go to original source... Go to PubMed...
    11. Maceira AM, Joshi J, Prasad SK. Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation 2005;111:195-202. Go to original source... Go to PubMed...
    12. Maurer MS, Schwartz JH, Gundapanenini B, et al. Tafamidis Treatment for Patients With Tranthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007-1016. Go to original source... Go to PubMed...
    13. https://www.ema.europa.eu/en/documents/product­‑information/vyndaqel­‑epar­‑product­‑information_cs.pdf.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.